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(460 mg/kg) using immunohistochemistry (IHC), transmis-
sion electron microscopy, and laser capture microdissection 
followed by LC-MS/MS for proteomic analysis. The histo-
logical examination demonstrated progressive neurodegen-
erative changes, astrogliosis, microglial activation, and calci-
fication in the hippocampal CA1 3–6 months after exposure. 
The IHC showed an increased staining for α-synuclein and 
ubiquitin in the area. The ultrastructural examination revealed 
intracellular deposition of abundant bundles of closely 
packed parallel fibrils in neurons, axons, and astrocytes 
of the CA1. Proteomic analysis of the affected site demon-
strated an enrichment of chaperones (e.g., clusterin, GRP-78), 
cytoskeletal and intermediate filament proteins, and proteins 
involved in the antioxidant defense system. Several of the 
most enriched proteins (plectin, glial fibrillar acidic protein, 
vimentin, Hsp 27, and ubiquitin) are known to form com-
plex astrocytic inclusions, so-called Rosenthal fibers, in the 
neurodegenerative disorder Alexander disease. In addition, 
TDP-43 and the negative regulator of autophagy, GLIPR-2, 
were exclusively detected. The present study demonstrates 
that neonatal exposure to BMAA may offer a novel model for 
the study of hippocampal fibril formation in vivo.
Keywords ALS/PDC · Alexander disease · α-Synuclein · 
Proteomics · TDP-43 · Ubiquitin
Introduction
Protein misfolding, intracellular fibrils, and extracellular 
deposits of plaques are hallmarks of many neurodegenerative 
diseases, including Alzheimer’s and Parkinson’s disease. The 
nonprotein amino acid and environmental neurotoxin β-N-
methylamino-l-alanine (BMAA) have been implicated in 
the etiology of neurodegenerative disease (Banack and Cox 
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2003; Pablo et al. 2009; Spencer et al. 1987), and behavio-
ral deficits have been demonstrated in rodents, monkeys, and 
insects exposed to BMAA (Karlsson et al. 2009c; Okle et al. 
2013; Spencer et al. 1987; Zhou et al. 2009). A recent in vitro 
study has suggested that BMAA can be misincorporated into 
proteins, which may result in the formation of protein aggre-
gates in cultured cells (Dunlop et al. 2013). Using whole-
body autoradiographic imaging, we have observed incorpo-
ration of radiolabelled BMAA into tissues with high protein 
synthesis following iv injection in mice, indicating a potential 
in vivo incorporation of BMAA as a false amino acid into 
proteins (Karlsson et al. 2009a). The access of BMAA to the 
adult rodent brain is, however, reported to be limited (Karls-
son et al. 2009a; Smith et al. 1992; Xie et al. 2013). In con-
trast, autoradiographic imaging revealed that radiolabelled 
BMAA is transferred across the blood–brain barrier in neona-
tal mice, with a distinct localization in specific brain regions 
such as the hippocampus (Karlsson et al. 2009b).
Radiolabelled BMAA is efficiently transferred to mother’s 
milk in rodents, and the subsequent transfer to the suckling 
pup results in a high exposure to the neonatal brain (Anders-
son et al. 2013). BMAA is a developmental neurotoxicant that 
can induce a suite of changes (Engskog et al. 2013; Karls-
son et al. 2009a, b, 2013a, b), including long-term learning 
and memory deficits (Karlsson et al. 2009c, 2011) as well as 
regionally restricted neuronal degeneration, necrosis, mineral-
ization, and astrogliosis in the adult rat hippocampus (Karls-
son et al. 2012). To understand the mechanisms of BMAA-
induced long-term neurobehavioral alterations, more studies 
on the effects of BMAA in the hippocampus are needed, as 
this brain area is essential for learning and memory.
The aim of the present study was to further characterize 
long-term changes in the hippocampus of adult rats treated 
neonatally (postnatal days; PND 9–10) with BMAA using 
histopathology, IHC, transmission electron microscopy, and 
proteomics. The results demonstrated that BMAA elicited 
extensive intracellular fibril formation, neurodegeneration, 
astrogliosis, microglial activation, and mineralization. The 
BMAA-induced changes in the hippocampus were progres-
sive, affecting more animals and displaying increased severity 
at later time points. Laser capture microdissection and sub-
sequent proteomic analysis of the histopathologically altered 
CA1 area demonstrated that several chaperones, cytoskeletal, 
and intermediate filament proteins were enriched.
Materials and methods
Chemicals
Unless otherwise stated, all chemicals were obtained from 
Sigma-Aldrich Co. (St. Louis, MO). β-N-methylamino-l-
alanine (L-BMAA) hydrochloride (≥97 %) was used.
Experimental design
The experimental design and doses were similar to those 
previously reported to induce cognitive and neurodegenera-
tive changes in adult animals (Karlsson et al. 2009c, 2011, 
2012). Pregnant outbred Wistar rats were obtained from 
Taconic (Ejby, Denmark). Each dam was housed alone in 
a Macrolon cage (59 × 38 × 20 cm) containing wood-chip 
bedding and nesting material. The animals were maintained 
on standard pellet food (R36 Labfor; Lantmännen, Kim-
stad, Sweden) and water ad libitum and were housed in a 
temperature-controlled and humidity-controlled environ-
ment on a 12-h light/dark cycle. On the day of birth (PND 
0), all litters were arranged to contain eight pups, with a 
homogeneous distribution of males and females. The male 
pups in each litter were randomly assigned to the control 
group or to one of the BMAA treatment groups. The male 
pups were administered one daily sc injection (20 μl/g) of 
BMAA 460 mg/kg (corresponding to 600 mg/kg BMAA 
HCl; n = 23) freshly dissolved in Hanks’ balanced salt 
solution or vehicle (n = 18) for 2 days on PND 9–10. After 
weaning on PND 22 and onward, 3 male rats were housed 
together in Macrolon cages in their respective treatment 
groups. All animal experiments were approved by the Upp-
sala Animal Ethics Committee and followed the guidelines 
of Swedish legislation on animal experimentation (Animal 
Welfare Act SFS1998:56) and European Union legislation 
(Convention ETS123 and Directive 86/609/EEC).
Histopathology and immunohistochemistry
The animals were killed by decapitation at 2 weeks (vehi-
cle n = 6, 460 mg/kg n = 7), 3 (vehicle n = 6, 460 mg/
kg n = 8), or 6 (vehicle n = 6, 460 mg/kg n = 8) months 
of age. The brain samples were immersed in cold 4 % 
phosphate-buffered formalin (pH 7.4). After fixation, the 
samples were embedded in paraffin and cut in 4-µm trans-
verse sections at a number of levels, including the olfac-
tory bulb, frontal cortex, basal ganglia, striatum, thalamus, 
hippocampus, and mesencephalon, including substantia 
nigra and pons. Samples of the liver and kidneys of all ani-
mals were likewise processed. The brain, liver, and kidney 
sections were stained with hematoxylin and eosin (H&E) 
and examined by light microscopy. Selected brain sections 
were stained with Congo Red, for identification of amy-
loids, periodic acid-Schiff (PAS), for detection of glycogen 
and glycoproteins, and von Kossa’s stain and Alizarin red, 
for detection of calcium. The histopathological changes 
were scored using the following grading system: 0 = none, 
1 = minimal, 2 = slight, 3 = moderate, and 4 = marked 
lesion.
Serial paraffin sections from the same brain levels 
as examined by H&E staining were used for IHC with 
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markers for α-synuclein, glial fibrillar acidic protein 
(GFAP), isolectin B4, transactive response DNA-binding 
protein 43 (TDP-43), tau protein, tubulin, and ubiquitin. 
IHC for these proteins (except isolectin B4) was performed 
using the staining module Discovery XT. Ventana® Medi-
cal Systems Inc., Tucson, AZ, USA, supplied all solutions 
for pretreatment, antibody dilution, detection, counter-
staining, and rinsing steps. IHC for detection of isolectin 
B4 was performed using the staining module IntelliPATH 
FLX. Biocare Medical, Concord, CA, USA, supplied all 
solutions for antibody dilution, detection, counterstaining, 
and rinsing steps. Details on primary and secondary anti-
bodies and detection systems used are provided in the Sup-
plemental Table 1. Slides stained without primary antibody 
(only antibody diluent in the primary antibody step) served 
as negative controls. Relevant positive controls were run in 
parallel.
Ultrastructural examination of neurons and astrocytes 
in the hippocampal CA1
Selected formalin-fixed brain samples of representative 
animals from both vehicle controls and BMAA-treated 
animals (3- and 6-month survival time points) were used 
for electron microscopy. The specimens were postfixed in 
3 % glutaraldehyde in 0.1 M Sorensen’s phosphate buffer, 
rinsed in buffer, and further fixed in 2 % OsO4 in 0.1 M 
Sorensen’s buffer. After a second rinse with buffer, the 
sections were dehydrated in increasing concentrations of 
ethanol and propylene oxide and embedded in epoxy resin. 
The embedded specimens were trimmed, and semithin 
and ultrathin sections were made using a Leica UC6 ultra 
microtome. The semithin sections (1 μm) were stained 
with 0.05 % toluidine blue. The ultrathin sections (70–
90 nm) were contrasted with 4 % uranyl acetate and lead 
citrate (Reynolds). Electron microscopy examinations were 
made using a Philips transmission electron microscope 
CM10. Images were taken with a Megaview II CCD cam-
era and captured using the AnalySIS computer program 
(Soft Imaging System, Münster, Germany).
Laser capture microdissection of the hippocampal CA1
One additional neonatal animal was treated with BMAA 
(460 mg/kg) as above and killed by decapitation at 
6 months of age. The distinct histopathological changes in 
the brain of this rat have previously been reported and are 
identical to the changes in BMAA-treated rats observed 
in the present study (Karlsson et al. 2012). Freshly pre-
pared coronal 20-μm cryosections of the brain from the 
BMAA-treated animal were mounted on PEN membrane 
slides (Carl Zeiss Microscopy GmbH). Histopathologically 
altered areas of hippocampal CA1, containing birefringent 
material, and ultrastructurally packed with fibrils were dis-
sected using a PALM MicroBeam AxioObserver inverted 
microscope (Carl Zeiss) equipped with a 355-nm pulsed 
laser for dissection (Fig. 1a–c) and contamination-free cat-
apulting into the cap of two tubes (Fig. 1d, e). Adjacent his-
tologically normal hippocampal CA1 areas were captured 
as control tissues (Fig. 1c). In total, 230,000 µm2 was col-
lected from the sample and control area each.
Identification of proteins enriched in the 
histopathologically altered hippocampal CA1 areas 
by proteomic analysis
The catapulted samples of the histologically altered hip-
pocampus CA1 and adjacent histologically normal areas 
were directly treated with trypsin for a two-step digestion 
in the capture tubes (500 µL of opaque adhesive), and LC-
MS/MS was performed. In brief, 25 µL of trypsin solution 
(0.5 µg/µL Promega sequencing grade trypsin, 200 mM 
triethylammonium bicarbonate, 1 % (w/v) sodium deoxy-
cholate, 10 mM dithiothreitol) was added, and the sam-
ples were incubated overnight at 37 °C. The supernatant 
in the caps was removed to a maximum recovery vial, and 
another 25 µL of trypsin solution was added for a second 
round of digestion (4 h, 37 °C). Digests were combined for 
each sample, and the deoxycholate content was removed 
by acid precipitation (adding 10 µL 10 % TFA followed by 
centrifugation at 13,000 rpm for 10 min). Finally, the sam-
ples were desalted using Pierce C18 spin columns (Thermo 
Fisher Scientific, Rockford, Il, USA) and reconstituted to 
a volume of 15 µL in 3 % acetonitrile and 0.1 % formic 
acid. For sample analysis, a volume of 3 µL (i.e., 20 % 
of the total sample) was injected for the nanoLC–MS/MS 
analysis.
NanoLC-MS/MS analysis was performed using a Q 
Exactive–Easy-nLC 1,000 instrument combination and a 
set of in-house packed columns. Briefly, the analytical col-
umn was a 75-µm ID × 200 mm PicoFrit column (New 
Objective Inc.) packed with ReproSil-Pur C18-AQ, 3-µm 
particles (Dr Maisch GmbH), and the trap column was 
100 µm ID × 45 mm of the same material.
Gradients of 125 min were run at a flow rate of 150 nL/
min (A-solvent: 0.2 % formic acid in water and B: 100 % 
acetonitrile). Mass spectrometry data acquisition param-
eters were set according to the “sensitive” parameters pro-
posed by Kelstrup et al. (2012), fragmenting the 12 most 
abundant precursors in each scan.
Protein identification was performed by searching 
the raw data against the UniProt Knowledgebase data-
base (UniProtKB/TrEMBL, download date November 
29, 2012) restricted by taxonomy to Rattus (a total of 
42,567 sequences) using the 2.3.2 release of the Mascot 
search engine. Search parameters were in brief as follows: 
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precursor tolerance: 10 ppm; fragment tolerance: 80 mmu; 
and dynamic modifications: oxidation (M), deamidation 
(NQ), methylthio (C), and missed cleavages: 1. Identifica-
tion results were limited to peptide assignments of ≥99 % 
confidence as assigned by Mascot. The false-discovery 
rate levels (1 % FDR) were 0.0063 and 0.0083 for sample 
and control searches, respectively, but 0.01 was chosen as 
the cutoff for the comparison. Comparison between hip-
pocampal CA1 areas with intraneuronal birefringent mate-
rial (sample) and adjacent CA1 areas without birefringent 
material (control) was based on the number of peptides 
identified for an assigned protein, which is indicative of 
protein abundance. Proteins that were identified by more 
peptides in the control tissues compared with the sam-
ple as well as proteins only detected by one peptide were 
discarded.
To verify the presence of ubiquitin, the laser-captured 
material was studied directly with MALDI TOF MS. 
Here, the collected tissue material was resuspended in 
5 µL of acetonitrile/water/TFA (50:50:0.1, v:v:v). The 
sample (1 µL) was spotted directly onto a MALDI target 
plate (MTP ground steel, Bruker Daltonics, Bremen, Ger-
many) followed by the addition of 1 µL of matrix solution 
(HCCA, 30 mg/mL, 50 % ACN, 0.1 % TFA). The sam-
ple was allowed to dry and subsequently analyzed with 
an Ultraflextreme MALDI TOF/TOF instrument (Bruker) 
running in linear positive mode. The delay time was set to 
250 ns, and the extraction voltage to 25 kV (IS1). The spec-
tra were calibrated externally with calibrant peaks (Protein 
Standard 1, Bruker) spotted adjacent to the sample.
Results
Histopathology and immunohistochemistry
The vehicle-treated control animals did not display any his-
topathological abnormalities in the brain, liver, or kidney at 
any survival time.
Two-week survival time
The BMAA-treated rats did not display any histopathologi-
cal changes in the studied brain regions (Table 1), liver, or 
kidneys compared to the vehicle-treated control animals.
Three‑month survival time
Four out of 8 rats treated with BMAA displayed 








Fig. 1  Hippocampal CA1 areas of a 6-month rat treated neonatally 
with BMAA on PND 9–10, showing deposition of birefringent mate-
rial within neurons (a) were collected using laser capture dissection 
(b). Examples of collected sample areas are shown in red and control 
tissue in green (c). The CA1 sample (d) and control tissue (e) were 
catapulted into the cap of the tube and directly treated with trypsin for 
a two-step digestion in the capture tubes, and LC-MS/MS was per-
formed
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remaining animals displayed histopathological lesions 
in the hippocampus exclusively confined to the CA1 seg-
ment (Table 1). Minimal to marked neuronal degenera-
tion and necrosis accompanied by intracellular deposition 
of a basophilic, birefringent material were observed in the 
CA1 (Fig. 2a). The birefringent material was demonstrated 
to contain calcium deposits using von Kossa and Alizarin 
red stainings (Fig. 2b). The mineralized neurons were also 
PAS-positive (not shown). Hypertrophic astrocytes were 
observed in close connection to the degenerating/mineral-
ized neurons within the CA1 area, with weak positive stain-
ing for ubiquitin (Fig. 2c) and a moderate increase in GFAP 
staining (Fig. 2d). A weak positive signal for α-synuclein in 
astrocytes and a moderate increase in isolectin B4 staining 
(indicating microglia activation) were also observed in the 
same region (not shown). Staining for amyloid with Congo 
red was negative, and the staining pattern/intensity for the 
TDP-43, tau, and tubulin marker did not differ between 
vehicle controls and rats treated with BMAA (not shown). 
In the other studied brain areas, the IHC and special stain-
ings indicated no differences between BMAA-treated rats 
and vehicle controls. The BMAA-treated rats did not dis-
play any histopathological changes in the liver, whereas 
there was a slight increase in intratubular hyaline droplets 
in the kidneys compared with the vehicle-treated control 
animals.
Six‑month survival time
Three out of 8 rats treated with BMAA did not display 
any histopathological abnormalities in the brain, whereas 
five rats displayed lesions in the hippocampal CA1 region 
(Table 1). Mineralization, degeneration, and necrosis of 
neurons were observed and graded in severity from mini-
mal to marked. In some animals, the CA1 neuronal layer 
was almost completely obliterated and replaced by hyper-
trophic astrocytes (Fig. 3a). Some of the astrocytes dis-
played an intensely eosinophilic cytoplasm reminiscent 
of the so-called Rosenthal fibers (Fig. 3b). The astrocytes 
within the CA1 area displayed strong positive staining for 
GFAP (Fig. 3c) and moderate positive staining for ubiqui-
tin (Fig. 3d) and α-synuclein (Fig. 3e). Increased isolectin 
B4 staining was also observed in the same region (Fig. 3f). 
Staining for amyloid with Congo red was negative, and the 
staining pattern/intensity for the TDP-43, tau, and tubulin 
marker did not differ between vehicle controls and rats 
treated with BMAA (not shown). In the other brain areas, 
the IHC and special stainings indicated no differences 
between the BMAA-treated rats and vehicle controls. The 
BMAA-treated rats did not display any histopathological 
changes in the liver and kidneys compared to the vehicle-
treated control animals.
Ultrastructural examination of neurons and astrocytes 
in the hippocampal CA1
In ultrathin sections of the hippocampal CA1 from repre-
sentative BMAA-treated rats at the 3- and 6-month survival 
time points, there were two major and distinct findings: 
intracellular aggregates of needle-like, electron-dense bod-
ies (crystals), and extensive fibril formation in the perikarya 
(Fig. 4a–h). Intracytoplasmic bundles of closely packed 
parallel-oriented fibrils, each with a diameter of approxi-
mately 10 nm, were abundant in neurons without (Fig. 4b–
d) and with intracellular crystals (Fig. 3e). The ultrastruc-
tural features of the crystals were consistent with calcium 
deposits. The fibrils were present both in the neuronal peri-
karya (Figure b–d) and in axons (Fig. 4f). Astrocytes also 
contained an abundance of closely packed fibrils, similar to 
those observed in the neurons, but crystals were not conclu-
sively identified in astrocytes (Fig. 4g–h). No extracellular 
crystals or fibrils were detected in the CA1 area.
Table 1  Histopathological changes in the hippocampus CA1 of rats 
treated neonatally with BMAA on PND 9–10
Neonatal rats on PND 9–10 were injected sc with BMAA (460 mg/
kg) and killed at various survival time points. Sections of paraffin-
embedded brains were stained and used for histopathological exami-
nation. Scoring system: 0 = none, 1 = minimal, 2 = slight, 3 = mod-
erate, and 4 = marked lesion
Time point Animal no. Scoring of histopathological lesions
2 Weeks 7–13 No histopathological changes


























428 Arch Toxicol (2015) 89:423–436
1 3
Identification of proteins enriched in the 
histopathologically altered area of the 
hippocampal CA1 by proteomic analysis
Histopathologically altered areas of hippocampus CA1, 
containing birefringent material, and ultrastructurally 
packed with fibrils from brain cryosections of a 6-month 
BMAA rat treated neonatally were isolated using laser cap-
ture microdissection. Adjacent histologically normal CA1 
areas on the same brain cryosections were captured as a 
control. The LC-MS/MS analysis detected 155 proteins 
in the control area and 203 proteins in the histopathologi-
cally altered area. Proteins that displayed higher levels in 
the control area as well as proteins that were only identified 
with one peptide were excluded. Finally, 120 proteins were 
considered to be enriched (at least 1.8-fold) or exclusively 
detected in the histopathologically altered areas in the hip-
pocampal CA1 (Supplemental Table 2). Several of these 
proteins are cytoskeletal components, intermediate fila-
ments, and chaperones and are implicated in protein aggre-
gation and fibril formation. Some of these 120 proteins, 
such as GFAP, connexin 43, phosphoglycerate kinase 1, 
alpha-enolase, and superoxide dismutase (SOD 1), are also 
markers of astrogliosis or involved in the energy metabo-
lism and the antioxidant defense system. The most enriched 
proteins (i.e., plectin, GFAP, vimentin, heat shock protein 
(Hsp 27), together with some specific proteins that are of 
special interest for neurodegenerative changes) are shown 
in Table 2.
Discussion
In this study, we report the intriguing intracellular deposi-
tion of bundles of parallel fibrils and calcifications in the 
hippocampal CA1 of adult rats exposed to the nonprotein 
amino acid BMAA during the neonatal period on PND 
9–10. Neurons and astrocytes contained an abundance of 
closely packed fibrils, whereas calcium crystals appeared 
to be confined to neurons only. The bundles of fibrils most 
likely interfere with cellular and axonal function because of 
their abundance, and they appear to be resistant to degra-
dation, suggesting that they are permanent changes at this 
site. The proteomic analysis of the affected site revealed an 
enrichment of chaperones, cytoskeletal, and intermediate 
filament proteins that previously have been implicated in 
Fig. 2  Histopathological changes in the hippocampal CA1 of rats 
treated neonatally with BMAA on PND 9–10, as examined at the 
3-month survival time point. Degenerating/necrotic neurons contain a 
basophilic, birefringent material (a) and demonstrated to contain cal-
cium using Alizarin red staining (b). Hypertrophic astrocytes within 
the same area display positive staining for ubiquitin (c) and GFAP 
(d). Magnification ×20
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protein aggregation and fibril formation. No histopatholog-
ical damage was observed 2 weeks after BMAA exposure, 
whereas distinct pathological changes in the hippocampus 
were present 3 and 6 months after BMAA exposure. Thus, 
the neurodegeneration, astrogliosis, and microglial activa-
tion in the CA1 area were progressive in nature, affecting 
more animals and displaying increased severity at later sur-
vival time points. Still, 3 out of 8 rats treated with BMAA 
did not display any distinct histopathological abnormalities 
in the hippocampus 6 months after exposure indicating an 
interindividual response to BMAA in the outbred Wistar 
rats with variation in their genome.
Intracellular deposition of fibrillar aggregates character-
izes several neurodegenerative diseases, but induction of 
intracellular fibril formation in vivo by exogenous agents 
is a rare finding, even though environmental factors are 
believed to play a major role in these complex disorders 
(Coppede et al. 2006). To our knowledge, this is the first 
ultrastructural observation of a nonprotein amino acid that 
induces extensive intracellular fibril formation in neurons 
Fig. 3  Histopathological changes in the hippocampal CA1 of rats 
treated neonatally with BMAA on PND 9–10, as examined at the 
6-month survival time point. Necrotic neurons are present as baso-
philic (mineralized) remnants, accompanied by marked astrocytosis 
(a). Some of the astrocytes display intensely eosinophilic cytoplasm, 
suggestive of Rosenthal fibers (b). The astrocytes show positive stain-
ing for GFAP (c) and ubiquitin (d). Magnifications: ×10 (a), ×20 (c), 
×40 (b, d)












Fig. 4  Ultrastructural features of neurons and astrocytes in the hip-
pocampal CA1 of rats treated neonatally with BMAA on PND 9–10, 
as examined at the 3-month survival time point. A normal control 
neuron is shown for comparison (a). Bundles of parallel-oriented 
fibrils are present in the cytoplasm of neurons without (b–d) and with 
(e) intracellular crystals. The appearance of the crystals is consist-
ent with calcium. The fibrils are present also in axons (f). In addi-
tion, an abundance of fibrils is present in the cytoplasm of astrocytes 
(g–h). Magnifications: ×5,800 (g) ×7,900 (a, b, f), ×25,000 (c, h), 
×46,000 (e), ×92,000 (d, f; inset)
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and astrocytes (Bell 2003; Rodgers 2013; Rubenstein 
2000). Many proteins exhibit propensities to form fibrils 
during in vitro conditions, but fibril formation in vivo is 
often because of misfolded or abnormally processed pro-
teins that have aggregated. Recent studies have indicated 
that BMAA may be misincorporated into proteins (Dunlop 
et al. 2013; Karlsson et al. 2009a, 2014). Interestingly, 
other amino acid analogs that are suggested to be misin-
corporated into proteins during synthesis may result in 
accumulation of misfolded proteins in cultured cells in 
vitro (Dasuri et al. 2011; Dunlop et al. 2008; Rodgers and 
Shiozawa 2008). The l-tyrosine mimetic l-DOPA has also 
Table 2  List of proteins 
enriched in a sample of 
histologically altered 
hippocampal CA1 areas of a rat 
treated neonatally with BMAA 
on PND 9–10, as examined at 
the 6-month survival time point
The CA1 sample containing 
birefringent material was 
compared with an adjacent 
CA1 sample not containing 
birefringent material
A neonatal rat on PND 
9–10 was injected sc with 
BMAA (460 mg/kg) and 
killed 6 months later. Twenty 
micrometer cryosections of 
the brain were used for laser 
capture microdissection and 
LC–MS/MS of the hippocampal 
CA1
a
 The number of different 
peptides detected for each 
protein (indicative of protein 
abundance) in the sample and 
the control, respectively
b
 The abundance ratio of pro-
teins from the sample versus the 
control
Protein Mw kDa Controla Samplea Abundance ratiob
Rosenthal fiber-associated proteins
 Plectin 519.7 2 48 24
 Glial fibrillary acid protein (GFAP) 49.9 17 133 7.8
 GFAP epsilon (fragment) 18.5 1 16 16
 Vimentin 53.7 3 68 22.7
 Heat shock protein (Hsp) 27 21.7 – 12 Exclusively detected
Other inclusion body-associated proteins
 Alpha-enolase 47.1 2 11 5.5
 Apolipoprotein E 35.7 1 7 7
 TAR DNA-binding protein 43 (TDP-43) 44.5 – 2 Exclusively detected
Chaperons
 Endoplasmin (GRP-94) 92.7 1 6 6
 Clusterin (apolipoprotein J) 51.4 – 3 Exclusively detected
 Glucose-regulated protein 78 (GRP-78) 72.3 2 8 4
Autophagy
 GLIPR-2 (GAPR-1) 16.7 – 6 Exclusively detected
Cytoskeletal proteins
 Actin, cytoplasmic 1 (beta-actin) 41.7 34 67 2
 Actin, alpha cardiac muscle 1 42 26 47 1.8
 Macrophage-capping protein 38.8 – 3 Exclusively detected
 Actin-depolymerizing factor (ADF; destrin) 18.5 2 4 2
Antioxidant system
 Glutathione S-transferase mu 1 26 – 6 Exclusively detected
 Glutathione S-transferase alpha-3 25.3 – 5 Exclusively detected
 Peroxiredoxin-1 22.1 – 4 Exclusively detected
 Peroxiredoxin-6 24.8 – 2 Exclusively detected
 Protein DJ-1 (PARK7) 20 2 5 2.5
 Superoxide dismutase (SOD1) 15.7 – 2 Exclusively detected
Lipid associated proteins
 Fatty acid- binding protein (FABP7) 14.9 – 6 Exclusively detected
 Annexin A1 38.8 – 2 Exclusively detected
 Annexin A2 38.7 – 4 Exclusively detected
 Annexin A3 36.3 – 11 Exclusively detected
 Annexin A4 35.8 – 4 Exclusively detected
 Annexin, anxa5 33.9 – 3 Exclusively detected
Glia markers and gliosis
 Excitatory amino acid transporter (EAAT) 1 59.6 – 2 Exclusively detected
 EAAT 2 60.9 3 6 2
 Gap junction alpha-1 protein (connexin 43) 43 1 6 6
 Histone H3 15.4 1 6 6
 Histone H2B 14 2 17 8.5
 Histone H1.4 22 1 9 9
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been reported to be incorporated into proteins of Parkin-
son’s disease patients treated with l-DOPA (Chan et al. 
2012; Rodgers et al. 2006). In addition, Lee et al. (2006) 
has demonstrated that low levels of mischarged tRNA 
cause intracellular accumulation of misfolded proteins and 
neurodegeneration in mice. Misincorporation of BMAA 
into proteins may therefore be a primary event resulting in 
fibril formation and neurodegeneration. Although it is not 
known whether the BMAA-induced fibrils are harmless or 
pathologic, the progression of the BMAA-induced lesions 
could indicate that potential misfolded proteins may seed 
misfolding of other proteins or serve to nucleate additional 
proteins, forming larger, potentially toxic protein aggre-
gates (Costanzo and Zurzolo 2013; Murphy 2002).
BMAA was identified in cycad seeds and demonstrated 
to be neurotoxic several decades ago because of its sug-
gested role in the etiology of the progressive neurodegen-
erative disorder amyotrophic lateral sclerosis/Parkinson-
ism-dementia complex (ALS/PDC) on the island of Guam 
(Banack and Cox 2003; Spencer et al. 1987). Several 
migrants from Guam have developed ALS/PDC decades 
after they have left the island. This lead Garruto and cow-
orkers to suggest that the etiological process had occurred 
in utero, during infancy, childhood, or adolescence (Gar-
ruto et al. 1980, 1984). Furthermore, it has been reported 
that exposure to cycads during young adulthood, but not 
adulthood, is a risk factor for neurodegenerative disorder 
among the inhabitants of Guam (Borenstein et al. 2007). 
BMAA has a low neurotoxic potency in adult rodents 
(Cruz-Aguado et al. 2006; Perry et al. 1989) compared to 
young animals (Karamyan and Speth 2008; Karlsson et al. 
2011). Taken together, the developing brain seems to be 
more vulnerable to BMAA. The exposure period PND 9–10 
used in the present study corresponds to the last trimes-
ter of pregnancy and the first few years of age in humans 
and is characterized by rapid maturation of neuronal sys-
tems (Dobbing and Sands 1979). Our recent studies show-
ing that BMAA is transferred via milk to suckling pups are 
therefore of particular interest for human risk assessment 
because they raise the possibility that exposure of breast-
fed infants to BMAA could occur (Andersson et al. 2013).
ALS/PDC is a severe tangle-forming disorder that 
affects both neuronal and glial cells (Miklossy et al. 2008). 
The neuropathology is characterized by neurofibrillary 
tangles of paired helical filaments (PHFs) composed of 
abnormally hyperphosphorylated forms of the protein tau, 
similar to those in Alzheimer’s disease (Miklossy et al. 
2008). Excitotoxic amino acids such as glutamate and 
aspartate are reported to induce PHFs in explant cultures of 
human neurons (De Boni and McLachlan 1985). Arif et al. 
(2014) recently found a decrease in protein phosphatase 2A 
(PP2A) activity associated with abnormal hyperphospho-
rylation of tau in brain of ALS/PDC patients. Interestingly, 
BMAA was reported to induce similar changes after icv 
exposure of neonatal rats by activating mGluR5 receptors 
(Arif et al. 2014). Although the IHC for tau in the present 
study failed to demonstrate a distinct increased staining in 
the histopathologically altered CA1 region, it cannot be 
excluded that hyperphosphorylation of tau could also play 
a role in the fibril formation in hippocampal CA1 neurons. 
However, BMAA-induced PP2A inhibition may also lead 
to hyperphosphorylation of other proteins that potentially 
could also result in intracellular fibril formation.
In addition to fibril formation, mineralization was 
detected in the CA1 neurons as demonstrated by staining 
with Alizarin red and von Kossa stains. Intraneuronal pre-
cipitation of calcium is known to occur following excessive 
activation of excitatory amino acid receptors in the brain, 
and it has been linked to Alzheimer’s disease and ALS/PDC 
(Garruto et al. 1984; Rodriguez et al. 2000). This is a likely 
mechanism for the observed mineralization as BMAA is a 
glutamate agonist that increases cytosolic calcium concen-
trations in brain slices and cultured neuronal cells (Copani 
et al. 1991; Cucchiaroni et al. 2010; Rao et al. 2006). More-
over, the glutamatergic receptors and their subunits often 
have transient peak levels during the first neonatal weeks in 
rats (McDonald and Johnston 1990; Ripellino et al. 1998). 
Calcifications have been suggested to serve as a protec-
tive buffer against free calcium ions (Mäkinen et al. 2007). 
Histochemical studies on some human neurological dis-
eases involving neuronal calcification (e.g., Fahr’s disease 
and Sturge-Weber syndrome) indicate storage of polysac-
charides and glycoproteins at the calcification sites (Ando 
et al. 1999). Indeed, increased PAS staining was detected in 
mineralized neurons in CA1, confirming the accumulation 
of glycogen and glycoproteins in these neurons of BMAA-
exposed neonatal rats.
Laser capture microdissection and subsequent LC-MS/
MS were used to characterize enriched proteins in the his-
topathologically altered CA1 area. A number of chaper-
ones, cytoskeletal, and intermediate filament proteins were 
found to be enriched in the affected area, and these pro-
teins have been implicated in protein aggregation and fibril 
formation. However, fibrils are usually resistant to agents 
employed to dissolve macromolecules, and the present 
protocol using trypsin, deoxycholate, and dithiothreitol for 
the proteomic analysis of the histologically abnormal areas 
may not necessarily have produced complete lysis and dis-
aggregation, which suggests that there may be additional 
proteins that are enriched. The enrichment of chaperones, 
cytoskeletal, and intermediate filament proteins may be a 
downstream/secondary response to the BMAA-induced 
intracellular formation of fibrils or the proteins they com-
prise. Different control systems, such as chaperones, ubiq-
uitin–proteasome system (UPS), and lysosomal autophagy, 
are active in defending against the hazards caused by the 
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accumulation of misfolded proteins (Lamark and Johansen 
2012). The neonatal exposure to BMAA appeared to acti-
vate these control systems as there was an enrichment of 
both chaperones and a recently identified negative regu-
lator of autophagy, GLIPR-2, also known as GAPR-1 
(Shoji-Kawata et al. 2013) in the affected hippocampal 
CA1 area. The latter was exclusively detected in this area. 
Thus, strategies that enhance autophagy via regulation of 
GLIPR-2 could possibly be used to reduce BMAA-induced 
toxicity (Shoji-Kawata et al. 2013). Interestingly, some of 
the BMAA-induced enriched proteins in the histopatho-
logically altered area, such as plectin, GFAP, vimentin, 
Hsp 27, and ubiquitin, are known to form complex astro-
cytic inclusions, the so-called Rosenthal fibers, in the neu-
rodegenerative disorder Alexander disease (Hagemann 
et al. 2009). In addition, some of the astrocytes displayed 
an intensely eosinophilic cytoplasm, which is also sugges-
tive of Rosenthal fibers. As with other protein aggregation 
disorders of the brain, it has not yet been fully resolved if 
the formation of Rosenthal fibers is harmful or protective 
(Ross and Poirier 2005). Experimental studies have demon-
strated that these fibers can originate from either expression 
of mutant GFAP or over-expression of wild-type GFAP and 
that elevation in total levels of GFAP may be a critical ele-
ment in the pathogenesis of Alexander disease (Hagemann 
et al. 2009; Jany et al. 2013).
Several chaperons, heat shock proteins, including Hsp 
27, endoplasmin (GRP-94), clusterin (apolipoprotein J), 
and GRP-78, which regulate nascent folding and modu-
late the fate of unstructured or misfolded proteins, were 
also found to be enriched in the affected CA1 area (Par-
cellier et al. 2003). Clusterin participates in Aβ, PrP(res), 
and α-synuclein aggregation in Alzheimer’s disease, pri-
onpathies, and α-synucleinopathies, respectively (Ferrer 
et al. 2005; Howlett et al. 2013; Sasaki et al. 2002). In addi-
tion, other inclusion body-associated proteins, such as the 
tauopathy-related protein alpha-enolase (Yang et al. 2008), 
apolipoprotein E, actin, the actin regulatory, macrophage-
capping protein, and actin-depolymerizing factor (ADF), 
also called destrin (Hirano 1994; Minamide et al. 2000), 
were found to be enriched.
The proteomic analysis of the histopathologically altered 
hippocampal CA1 also revealed an enrichment of proteins 
important for the antioxidant defense system, which con-
firms the ability of BMAA to induce oxidative stress (Liu 
et al. 2009; Okle et al. 2012). In addition, there was an 
enrichment of glutathione S-transferase as well as perox-
iredoxin, PARK7, and SOD1 in the damaged CA1 area, 
which indicates an activation of the antioxidant system 
in the brain of adult rats neonatally treated with BMAA. 
Furthermore, TDP-43, which is a major constituent of the 
proteinaceous inclusions that are characteristics of ALS 
(Lee et al. 2012) and found in ALS/PDC (Maekawa et al. 
2009; Miklossy et al. 2008), was exclusively detected in 
the affected CA1 area. This is in line with our preliminary 
observation on fibril formation (Brittebo et al. 2012) and 
recent studies suggesting that BMAA may induce TDP-43 
in neonatal rats and SH-SY5Y human neuroblastoma cells 
(de Munck et al. 2013; Munoz-Saez et al. 2013). However, 
the presence of TDP-43 in the affected CA1 area could not 
be confirmed with IHC and the antibody used in the current 
study.
In our previous study, hippocampal CA1 neurons of 
BMAA-treated rats displayed increased staining for both 
ubiquitin and α-synuclein compared with controls (Karls-
son et al. 2012). This result could not be reproduced in 
the present study, and an increased staining for these two 
markers was only found in astrocytes. The reason for this 
discrepancy is most likely related to differences in method-
ology. In the first study, cryosections were used to preserve 
mineralized neurons. In the present study, we used forma-
lin-fixed, paraffin-embedded tissue sections to obtain better 
morphological resolution. As a consequence, many miner-
alized and damaged neurons were lost from the slides, pre-
cluding a reliable assessment of ubiquitin and α-synuclein 
IHC staining in these cells. Judging from the staining 
intensity in astrocytes in the brain of adult rats treated neo-
natally with BMAA, the increase in ubiquitin as well as 
α-synuclein is a late event in the pathogenesis of BMAA-
induced neurotoxicity and is not clearly evident until the 
6-month survival time point. Accumulation of α-synuclein, 
involving not only neurons but also astrocytes, has been 
observed in the brain of Guamanian ALS/PDC patients 
(Sebeo et al. 2004). In a series of in vitro studies, an inter-
esting link between α-synuclein and calcium has recently 
been demonstrated. Calcium promoted α-synuclein aggre-
gation both by itself (Nath et al. 2011) and cooperatively 
with oxidative stress (Goodwin et al. 2013).
Enriched levels of excitatory amino acid transporter 
(EAAT) 1 and 2, glial fibrillary acidic protein (GFAP), 
vimentin, and connexin 43, which are markers of glia 
cells and astrogliosis, were detected by LC-MS/MS in 
the affected CA1. In addition, the increase in several his-
tones confirms our previous MALDI IMS study showing 
an increased expression of histones H2 and H3 in CA1 
(Karlsson et al. 2012) and corresponds to the marked astro-
gliosis and activation of microglia at this site observed 
by IHC. The activated glia and over-expression of their 
secreted cytokines could start a self-propagating cycle lead-
ing to neurotoxicity, which may be one additional mecha-
nism behind the observed progression of the lesions in the 
BMAA-treated animals. Finally, brain lipid-binding pro-
tein (FABP7), which is known to modulate astrocyte func-
tion, was enriched in the affected CA1 area (Kipp et al. 
2011). Several annexins, also called lipocortins, were also 
enriched. Annexins are characterized by their ability to 
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bind phospholipids and could suppress phospholipase A2. 
Therefore, it is important to study the effect on lipids and 
fatty acids in the BMAA-treated animals.
Conclusions
Considerable evidence supports a multifactorial etiology 
involving both environmental and genetic factors in neuro-
degenerative disease. Several genetically engineered mouse 
models of neurodegenerative disease are available to study 
protein aggregation processes and behavioral impairments. 
However, the sporadic formation of fibrils in vivo is less 
studied. The present study demonstrates that neonatal expo-
sure to the excitotoxic nonprotein amino acid BMAA may 
offer a novel animal model for the study of fibril formation 
in the hippocampus in vivo. The critical cellular perturba-
tions preceding fibril formation, such as excitotoxicity, 
oxidative stress, misincorporation of BMAA into proteins, 
or other processes, remains to be elucidated. Although sev-
eral caveats must be noted when comparing the BMAA-
induced intracellular formation of fibrils with the pathol-
ogy in human neurodegenerative disease, the present data 
suggest that further studies to elucidate the key molecular 
initiating event of BMAA-induced long-term neurodegen-
erative effects are warranted.
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